bmi for tirzepatide Effect of on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity New drug tirzepatide delivers significant

Anthony Rossi, a dermatologist at Memorial Sloan Kettering Cancer Center, said telogen effluvium often appears after a period of stress, such as childbirth, anesthesia or crash dieting

Spicy foods may also bother the digestive system

Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J

Food intake was determined from 10:30 to 11:30

RCT STEP 9 - Semaglutide vs Placebo for Knee Osteoarthritis in Patients with Obesity, NEJM (2024) [PubMed abstract] The STEP 9 study enrolled 407 patients with BMI 30 and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain Main inclusion criteria Age 18 years or older BMI 30 ACR diagnostic criteria for knee OA Moderate X-ray changes (Kellgren-Lawrence grade 2 or 3) in target knee Knee OA WOMAC pain score of 40 Main exclusion criteria Use of opioid medications Use of obesity medication within 90 days Knee injection within 90 days Baseline characteristics Average age - 56 years Average weight - 239 lbs (108.6 kg) Average BMI - 40.3 Female sex - 82% Average WOMAC pain score - 70.9 Randomized treatment groups Group 1 (271 patients): Semaglutide 2.4 mg once weekly Group 2 (136 patients): Placebo Semaglutide was started at 0.24 mg once weekly and titrated over 16 weeks to 2.4 mg The percentage change in body weight and the change in the WOMAC pain score (scale 0 - 100, with higher scores meaning worse outcomes) from baseline to week 68 Primary outcome: Results Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo

This approach provides enough receptor activation to blunt appetite return without the full side effect profile or cost of standard doses